Kymab wins UK court case against Regeneron’s patent claims
The UK Supreme Court has ruled that Regeneron's patent claim…
The UK Supreme Court has ruled that Regeneron's patent claim regarding genetically modified mice against Kymab are invalid.
List view / Grid view
The UK Supreme Court has ruled that Regeneron's patent claim…
The UK Supreme Court has ruled that Regeneron's patent claim regarding genetically modified mice against Kymab are invalid.
"We are very pleased to partner with Apexigen..."
5 December 2012 | By Boehringer Ingelheim
"We are very pleased to partner with Apexigen..."
Boehringer Ingelheim and Molecular Partners have entered into a strategic…
12 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Molecular Partners have entered into a strategic manufacturing collaboration...
Boehringer Ingelheim announced an agreement with Servier & its partner…
3 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced an agreement with Servier & its partner XOMA Corporation...
Boehringer Ingelheim BioXcellence: Distinctive brand for the biopharmaceutical contract manufacturing…
18 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim BioXcellence: Distinctive brand for the biopharmaceutical contract manufacturing business...
Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody…
21 February 2012 | By Boehringer Ingelheim
Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life...
Boehringer Ingelheim has expanded its biopharmaceutical cell line development services...
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has expanded its biopharmaceutical cell line development services...
Boehringer Ingelheim wins the '2011 European Bio Pharmaceutical Contract Manufacturing…
7 September 2011 | By Boehringer Ingelheim
Boehringer Ingelheim wins the '2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award'...
Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing…
10 August 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology...
To round off its full-service capabilities for clients, Boehringer Ingelheim…
20 June 2011 | By Boehringer Ingelheim
To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill & finish for biopharmaceuticals at their state-of-the-art facility in Biberach, Germany, with a new filling line.
Yesterday Boehringer Ingelheim formally acquired Amgen’s biopharmaceutical development and manufacturing…
Yesterday Boehringer Ingelheim formally acquired Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California (USA)...
Announcement covers global technical development and manufacturing for antibody-based therapeutics...
9 February 2011 | By Boehringer Ingelheim
Announcement covers global technical development and manufacturing for antibody-based therapeutics...